97 results about "Acute promyelocytic leukemia" patented technology

The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also provides methods for making the oral arsenic trioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.

The invention provides an electrochemical DNA biosensor for detecting PML/RAR alpha fusion gene of acute promyelocytic leukemia. The gene to be detected is the PML/RAR alpha fusion gene of the acute promyelocytic leukemia (APL); and the method comprises the following steps: (1) designing and synthesizing a specific sequence of the APL according to the selected fusion sites of a universal primer sequence of the gene type of the APL to be detected; and (2) constructing a nano modified electrode by a Au nano material, and constructing the nano electrochemical biosensor used for detecting the PML/RAR alpha fusion gene of the APL by the electrochemical enzyme-linked immunoassay technology. The method greatly improves the sensitivity of the biosensor so as to realize early diagnosis of the acute promyelocytic leukemia.

The invention relates to a detection kit for detecting the relative expression level of PML-RAR (alpha) fusion gene by use of fluorescent quantitative PCR (polymerase chain reaction) technology. The detection kit comprises the following materials in part ratio: red blood cell lysis buffer, TRIzol, chloroform, absolute ethyl alcohol, reverse transcription PCR reagent, detection system PCR reaction liquid, positive control substance and negative control substance. The kit provided by the invention has the advantages that the precision is high, the result is convenient to read, both the amplification efficiency and the rate reach the best level and the like; the complicated condition grope link is omitted; and the experimental efficiency is greatly improved. The kit has good specificity and high sensitivity and is easy and convenient to operate according to the test. The detection kit is favorable for the trace residue detection of the PML-PAR (alpha) (type L/type S) fusion gene in a clinical APL (acute promyelocytic leukemia) patient, and has great importance in performing timely intervention therapy to avoid hematological recurrence, adjusting the therapeutic schedule, evaluating the therapeutic effect, predicting the prognosis and preventing clinical recurrence.

The invention relates to a kit for the mRNA expression level of a PML-RARa fusion gene, and belongs to the field of biotechnology. The kit comprises a PML-RARa L fusion gene system, a PML-RARa V fusion gene system or a PML-RARa s fusion gene system and a reference gene system ABL, wherein each system comprises an upstream primer and a downstream primer and Taqman fluorescence probe. The PML-RARa fusion protein, as a variant retinoic acid receptor, has different DNA properties with a wild type RARa protein and is an intrinsic and effective repressor for retinoic acid (RA) signal which is the transcription factor of an intrinsic RARa target gene. Therefore, when the fluorescence quantitative polymerase chain reaction (PCR) method is used for detecting the mRNA expression level of the PML-RARa fusion gene, the detection result is more specific and sensible. The kit provides a novel quick and simple genetic diagnosis technology for predicting the prognosis of acute promyelocytic leukemia and determining chemotherapy regimens.

The present invention addresses the problem of providing an Fms-like tyrosine kinase 3 (FLT3) inhibitor that is useful as a therapeutic agent for acute myeloid leukemia (AML). Provided is a novel nitrogen-containing heterocyclic compound represented by general formula [1] or a salt thereof. The compound according to the present invention or a salt thereof is usable as the active ingredient of a medicinal composition for treating diseases or conditions relating to FLT3 such as AML and acute promyelocytic leukemia (APL).

The invention relates a PML gene and RARA gene detection probe and a preparation method thereof. The method comprises the following steps that at least one of RP11-832J18, CTD-2529B11, RP11-756N20 and RP11-1031J4 and a selected BAC cline for an RARA gene is at least one of CTD-2360L10, RP11-737D6, CTD-3087O22, RP11-48O10 and CTD-2134K5 are included; a plasmid DNA is obtained; labeling is performed. The invention further discloses a reagent kit containing the PML gene and RARA gene detection probe for detecting acute promyelocytic leukemia PML and RARA fusion genes. The optimal PML gene and RARA gene detection probe is obtained through screening, the signal counting row is accurate and rapid, and the result repeatability is good.

The invention provides a preparation method of thrombus removing and collaterals dredging tablets. The thrombus removing and collaterals dredging tablets are prepared by performing supercritical extraction on 120 g of ligusticum wallichii, 90 g of salviae miltiorrhizae, 180 g of astragalus membranaceus, 60 g of alisma orientalis, 60 g of pseudo-ginseng, 30 g of flos sophorae, 60 g of cassia twig, 60 g of curcuma aromatica, 30 g of elecampane, 2.4 g of borneol and 60 g of hawthorn serving as raw materials, so that the content of each raw material is greatly improved, and the dose is reduced. The invention also provides application of the thrombus removing and collaterals dredging tablets in preparation of a medicament for inhibiting the cell proliferation of human acute promyelocytic leukemia cell NB4.

The invention provides a preparation method of an antiphlogosis tablet which is prepared from crude drugs including 446g of dandelion, 446g of herba violae, 446g of wild chrysanthemum and 446g of radix scutellariae through supercritical extraction and microwave extraction, so that the content of baicalein is greatly improved. The invention also provides the application of the antiphlogosis tablet in preparing a medicine for restraining proliferation of human acute promyelocytic leukemia cell, NB4 cell.

The present invention is degradable polymer supported nanometer Daunorubicin microsphere and its preparation process. The microsphere has size of 200-800 nm, Daunorubicin carrying rate of 3.05-18.4 %, encapsulating rate of 53.2-88.3 %, and degradable polymer polylactic acid or polylactic acid-polyglycolic acid copolymer. Experiment shows that the nanometer Daunorubicin microsphere may be released continuously in buffering phosphate solution for 2-8 weeks and the releasing rate and period may be controlled through changing the sort and molecular weight of the polymer. The nanometer Daunorubicin microsphere is superior to conventional Daunorubicin preparation, and has higher acute promyelocytic leukemia cell ingesting efficiency, higher tumor cell inhibiting rate and long effective period.

The invention discloses a tetracyclic diterpenoid compound and a preparation method as well as application thereof. The tetracyclic diterpenoid compound is obtained through extractum extracting, organic solvent leaching, column chromatography on silica gel and high pressure liquid chromatography separation by taking Araliadumetorum Hand.-Mazz roots as a material. The compound has a molecular formula of C20H30O3, is named as dumetorumane B, and has the following structural formula as shown in the description. The preparation method means that the tetranuclear diterpenoid is obtained through extractum extracting, organic solvent leaching, column chromatography on silica gel and high pressure liquid chromatography separation by taking the Araliadumetorum Hand.-Mazz roots as the material. The application is application of the tetranuclear diterpenoid to preparation of drugs for preventing and/or treating tumour and to preparation of drugs for preventing and/or treating human lung adenocarcinoma, human acute promyelocytic leukemia or human breast cancer. The tetranuclear diterpenoid has a remarkable inhibiting effect on cell strains of human lung adenocarcinoma, human acute promyelocytic leukemia or human breast cancer, has good antitumor activity indicatively, and can serve as an antitumor activity component or a lead compound.

The invention provides an application of Prx I/II in screening of medicaments for treating leukemia, wherein the Prx I/II is used as a medicament target to screen medicaments which inhibits PRX I/II enzyme activity and thus has a differentiation effect on leukemia cells. According to the invention, screened adenanthin and derivatives thereof are used for realizing the differentiation effect for acute promyelocytic leukemia, thereby showing significant effects for treating all-trans retinoic acid sensitive and all-trans retinoic acid resistant leukemia. The adenanthin is safe, low in toxicity and strong in pharmacological effect, and indicates good medicinal prospects. The adenanthin active substance provided by the invention has characteristics of easy absorption, good stability, etc., and is relatively suitable for developing as novel medicaments, foods, health products or dietary additives.

The invention discloses emodin as an inhibitor of activated molecules p-Akt and p-mTOR of a PI3K/Akt/mTOR signal transduction pathway and application thereof, wherein the emodin is a purely natural anthraquinone monomer compound extracted from rhubarb as a Chinese traditional medicine and has multiple biologic activities such as anti-microbes, anti-inflammation, antioxidation, immune regulation, liver protection and the like. The invention finds that after acute leukemia multidrug-resistance cells HL-60/ADR, acute promyelocytic leukemia retinoic acid drug-resistant cells MR2 as well as corresponding sensitive cells NB4 and acute leukemia primary cells are acted by the rhubarb, key signal activated molecules of the PI3K/Akt/mTOR signal transduction pathway, particularly p-Akt and p-mTOR, are inhabited with specificity; in vivo researches verify that after the emodin is dosed, all the key activated molecules p-Akt, p-p65 and p-mTOR of the PI3K/Akt/mTOR signal pathway in acute leukemia nude mouse transplanted tumor tissue protein are expressed and downwards regulated, which indicates that the emodin can be used as a novel targeting inhibitor for PI3K/Akt/mTOR signal transduction activated molecules, particularly p-Akt and p-mTOR, and is applied to treating malignant tumors of a blood system.

The invention relates to a method for measuring the concentrations of four arsenic compounds in granulocytes by using an HPLC (High Performance Liquid Chromatography)-ICP (Inductively Coupled Plasma)-MS method and an application, and belongs to the technical field of blood sample detection. In order to solve the problem that the existing method cannot accurately measure the concentrations of fourdifferent arsenic compounds AsIII, AsV, DAV and MMVA in granulocytes, the invention provides a method for measuring the concentrations of four arsenic compounds in granulocytes by using the HPLC-ICP-MS method. The method comprises the steps of determining a detection condition, preparing a standard solution, drawing a standard curve, collecting and processing a granulocyte sample, performing sample detection and data processing. According to the method for measuring the concentrations of four arsenic compounds in granulocytes by using the HPLC-ICP-MS method and the application, each arsenic compound in granulocytes can be effectively extracted and accurately quantified. When the method is applied to the detection of the concentrations of four arsenic compounds in peripheral blood granulocytes of a patient suffering from APL (Acute Promyelocytic Leukemia, the metabolism and distribution characteristics of each arsenic form can be clarified, a technical basis is provided for revealing ofthe action mechanism of arsenic acid and reduction of toxic reactions, and when the method is used for assisting clinics, personalized medicine and targeted therapy are implemented.

The invention belongs to the field of medicine technologies, and relates to two benzyl isoquinoline alkaloid compounds containing a chlorine substitutent, which have antitumor activity and are separated from Thalictrum foliolosum. The compounds provided by the invention are novel in structure, have remarkable in vitro antitumor activity for a human acute monocytic leukemia cell line U937, a human acute promyelocytic leukemia cell line HL-60, a human breast cancer cell line MCF-7 and a human prostate cancer cell line PC-3, and can be a lead compound used for developing a novel antitumor natural medicine.

The invention relates to a medicine composition which is used for treating leukemia and contains idelalisi and application, belongs to the medical field and provides the medicine drug containing idelalisi in order to reduce the toxic and side effects of existing leukemia treating medicine of idelalisi and further enhance the treatment effect of idelalisi on leukemia. By means of the medicine composition, growth of acute promyelocytic leukemia NK4 cells, chronic myelogenous leukemia K562 cells and retinoic-acid-resistant promyelocytic leukemia MR-2 cells of a person can be remarkably reduced, and active components of two kinds of medicine have a remarkable synergistic effect on treating leukemia. The medicine composition has the advantages that the components are clear, the toxic and side effects are small, and the treatment effect is good, and the medicine composition is suitable for being popularized clinically and used for treating leukemia.

The current invention is directed to a class of compounds that inhibit the function of Thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells. Thymidylate synthase inhibition is, thus, useful for treatment of various types of cancers, including but not limited to, acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer and breast cancer. The compounds disclosed herein can be used alone or in combination with other cancer treatment regimens (e.g., radiation therapy and/or other chemotherapeutic agents that are administered to a subject having a tumor, cancer or neoplasia).

The invention discloses a method for detecting relative expression levels of TBLR1-RAR alpha and PRKAR1A-RAR alpha fusion genes by using a fluorescent quantitative PCR technology. The method uses a primer and a probe with specificity. The method can be used for detecting expression levels of the fusion genes such as TBLR1-RAR alpha, PRKAR1A-RAR alpha and PRKAR1A-RAR alpha inside acute promyelocytic leukemia (APL) patients. The method can be used as one of evidences for selection and formulation of APL individual treatment schemes, and is significant for adjusting the treatment schemes, evaluating treatment effect, predicting prognosis and preventing clinical recurrence.

The invention relates to the technical field of medicines, and relates to a novel natural medicine having anti-tumor functions and extracted and separated from dictyopteris undulata Holmes in China. The medicine is a steroid compound that is dictyopterisin F. In-vitro anti-tumor activity tests prove that IC50 values of the compound for human acute promyelocytic leukemia cells (HL-60) and human lung cancer cells (A-549) are 2.45 [mu]M and 2.85 [mu]M respectively, and therefore the compound can be used for preparing anti-tumor medicines, can be prepared into anti-tumor medicine compositions withother medicines, and can be prepared into injections, tablets, pills, capsules, solutions, suspensions, emulsions, and other dosage forms with pharmaceutically acceptable auxiliary materials, and administration routes of the compound can be oral administration, intravenous administration, intramuscular administration or percutaneous administration.

The invention provides oligonucleotide and detection method for detecting the expression level of a NPM1-RARa fusion gene in the body of a patient suffering from acute promyelocytic leukemia. The oligonucleotide comprises a primer and probe for detecting the NPM1-RARa-1 and NPM1-RARa-2 fusion genes. A real-time fluorescence PCR technology and a double-standard curve method using a detection primerand probe of a target gene and a reference gene are adopted, so that expression levels of fusion genes NPM1-RARa-1 and NPM1-RARa-2 in the body of the patient suffering from APL can be detected. The detection time can be effectively saved, and the detection precision is improved. Besides, the oligonucleotide and the detection method can be used as one of bases for selecting and formulating an APLindividualized treatment scheme, have important significance for adjusting a treatment scheme, evaluating the treatment effect, predicting prognosis and intervening treatment in time to avoid hematological recurrence, and are convenient for clinically performing individualized treatment.

The invention discloses a calf spleen extract for treating tumors, which contains 5 to 15 weight parts of polypeptides and 0.4 to 1 weight part of ribose. The extract can obviously inhibit tumors, resist mouse white blood cell reduction caused by cyclophosphamide chemotherapeutics and invert the inhibition of cyclophosphamide on bone marrow cells, and the extract can treat acute promyelocytic leukemia.

The invention provides 3-amino-3-arylpropionic acid with the structure shown in the formula I in the specification, wherein R1 is substituted or non-substituted phenyl, substituted or non-substituted bicyclo or tricycloaryl or substituted or non-substituted monocyclo, bicyclo or tricycloaryl containing at least an N, O or S atom. The invention also provides a preparation method of 3-amino-3-arylpropionic acid. The unnatural amino acid 3-amino-3-arylpropionic acid can synthesize a series of polypeptide compounds with other amino acids. The polypeptide compounds have certain inhibitory activity against histone deacetylase (HDAC), are possibly used for preventing or treating diabetes, diabetes complications, acute promyelocytic leukemia (APL), inflammatory diseases, organ transplantation rejection, protozoan infection, autoimmune diseases or tumors, etc and have certain medicinal value. The preparation method has the beneficial effects of easily-obtained raw materials, simpleness, convenient operation and higher yield.

The invention provides an aptamer specifically combining acute promyelocyte leukemia HL-60 cells, and further provides a screening method and a clinical application of the aptamer. According to the screening method, six types of aptamers with different sequences are screened, and combining capacity among the aptamers and the acute promyelocyte leukemia HL-60 cells is different. The screening method includes the steps: synthesizing random single-strand DNA (deoxyribonucleic acid) libraries and primers; performing Cell-SELEX screening; performing library amplification; preparing a DNA single-strand library; repeating multiple screening and subduction screening; detecting stability after screening; detecting specificity of the aptamers.

The use of eriocalyxin B in the manufacture of medicaments for treating leukemia, wherein the leukemia include leukemia containing AML1-ETO fusion protein, acute promyelocytic leukemia, acute myelocytic leukemia and lymphocytic leukemia. Eriocalyxin B increases the level of peroxidate and influences the phosphorylation and degradation of IκBα to prevent NF-κB from getting into the nucleus in order to inhibition NF-κB pathway. Eriocalyxin B can decrease the phosphorylation of ERI1/2 and inhibit MAPK pathway. Eriocalyxin B can extend the life span of mice and decrease tumor volume in mice model of C57 leukemia and tumor transplantation.

The invention discloses a tricyclic diterpenoid compound and a preparation method and application thereof. The tricyclic diterpenoid compound is obtained by taking aralia melanocarpa stems as raw materials through extract leaching, organic solvent extraction, silica gel column chromatography and high pressure liquid chromatography separation. The molecular formula of the compound is C20H32O4, the compound is named dumetorumane A, and the structural formula of the compound is as shown in the specification. The preparation method comprises the following steps: by taking the aralia melanocarpa stems as the raw materials, carrying out extract leaching, organic solvent extraction, silica gel column chromatography and high pressure liquid chromatography separation so as to obtain the tricyclic diterpenoid compound. The tricyclic diterpenoid compound can be applied to preparation of medicines for preventing and/or treating tumors and can be applied to preparation of medicines for preventing and/or treating human lung adenocarcinoma, human acute promyelocytic leukemia or human breast cancer. The tricyclic diterpenoid compound has obvious inhibiting effects on human lung adenocarcinoma, human acute promyelocytic leukemia or human breast cancer cell strains, has favorable anti-cancer activity, and can serve as an anti-cancer active ingredient or a lead compound.